Neil Pegg

1.2k total citations
39 papers, 465 citations indexed

About

Neil Pegg is a scholar working on Molecular Biology, Organic Chemistry and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Neil Pegg has authored 39 papers receiving a total of 465 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 14 papers in Organic Chemistry and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Neil Pegg's work include Protein Degradation and Inhibitors (16 papers), Chemical Synthesis and Analysis (10 papers) and Prostate Cancer Treatment and Research (9 papers). Neil Pegg is often cited by papers focused on Protein Degradation and Inhibitors (16 papers), Chemical Synthesis and Analysis (10 papers) and Prostate Cancer Treatment and Research (9 papers). Neil Pegg collaborates with scholars based in United Kingdom, United States and Sweden. Neil Pegg's co-authors include Brian Evans, Leo A. Paquette, Andrea Basso, Mark Bradley, Harry Finch, D. Michael Gill, Gerald Pattenden, Christopher M. Rayner, Robin D. Rogers and Nigel Brooks and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Clinical Oncology and Blood.

In The Last Decade

Neil Pegg

39 papers receiving 435 citations

Peers

Countries citing papers authored by Neil Pegg

Since Specialization

Citations

This map shows the geographic impact of Neil Pegg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil Pegg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil Pegg more than expected).

Fields of papers citing papers by Neil Pegg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil Pegg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil Pegg. The network helps show where Neil Pegg may publish in the future.

Co-authorship network of co-authors of Neil Pegg

This figure shows the co-authorship network connecting the top 25 collaborators of Neil Pegg. A scholar is included among the top collaborators of Neil Pegg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil Pegg. Neil Pegg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Therapeutic targeting of the p300/CBP bromodomain enhances the efficacy of immune checkpoint blockade therapy 2025 ·Oncogene ·Jinghui Liu, Xinyi Wang, Daheng He, (unknown), (unknown), (unknown), (unknown), Xiongjian Rao, Ruixin Wang, Sai Wu, (unknown), Nigel Brooks, Neil Pegg, (unknown), Zhiguo Li, Xiaoqi Liu	4
2	Tolerability and Clinical Activity of Novel First in Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma 2023 ·Blood ·Emma Searle, James Cavet, (unknown), Steven Knapper, Ceri Bygrave, Dima El‐Sharkawi, Charlotte Pawlyn, Maria Creignou, Harriet S. Walter, David Valcárcel, (unknown), Jenny O’Nions, (unknown), (unknown), (unknown), Neil Pegg, (unknown), (unknown), (unknown), Tim C. P. Somervaille	1
3	Potent Pre-Clinical and Early Phase Clinical Activity of EP300/CBP Bromodomain Inhibitor CCS1477 in Multiple Myeloma 2022 ·Blood ·(unknown), Nigel Brooks, Fabio M. R. Amaral, (unknown), Neil Pegg, William H. West, (unknown), (unknown), (unknown), James Cavet, Emma Searle, Tim C. P. Somervaille	6
4	Therapeutic Targeting of EP300/CBP By Bromodomain Inhibition in Acute Myeloid Leukemia 2022 ·Blood ·(unknown), Gary J. Spencer, Nigel Brooks, Fabio M. R. Amaral, (unknown), (unknown), (unknown), Bettina Wingelhofer, Alba Maiqués-Díaz, Filippo Ciceri, Daniel H. Wiseman, Neil Pegg, William H. West, (unknown), (unknown), (unknown), Victoria Campbell, Mhairi Copland, Emma Searle, Tim C. P. Somervaille	4
5	560TiP A phase I/IIa study to evaluate the safety and efficacy of CCS1477, a first in clinic inhibitor of p300/CBP, as monotherapy in patients with selected molecular alterations 2021 ·Annals of Oncology ·Simon J. Crabb, Ruth Plummer, Alastair Greystoke, (unknown), Simon Pacey, Harriet S. Walter, Vicky M. Coyle, (unknown), (unknown), (unknown), Neil Pegg, W. H. West, Nigel Brooks, (unknown), Johann S. de Bono	6
6	CCS1477, a Novel p300/CBP Bromodomain Inhibitor, Enhances Efficacy of Azacitidine and Venetoclax in Pre-Clinical Models of Acute Myeloid Leukaemia and Lymphoma 2021 ·Blood ·Nigel Brooks, (unknown), Andrew Hughes, (unknown), William H. West, Neil Pegg, Gary J. Spencer, (unknown), Tim C. P. Somervaille	9
7	Preclinical investigation of a small molecule inhibitor of p300/CBP reveals efficacy in patient-derived prostate tumor explants. 2019 ·Journal of Clinical Oncology ·Lisa M. Butler, Swati Irani, Margaret M. Centenera, Natalie K. Ryan, Neil Pegg, A. Nigel Brooks	2
8	Abstract 3991: Novel small molecule inhibitors of p300/CBP down-regulate androgen receptor (AR) and c-Myc for the treatment of prostate cancer and beyond 2018 ·Cancer Research ·Neil Pegg, Jenny Worthington, Barbara Young, Amy Prosser, Luke Gaughan, Gary J. Spencer, Tim C. P. Somervaille, Julie E. Burns, Margaret A. Knowles, Nigel Brooks	3
9	Characterisation of CCS1477: A novel small molecule inhibitor of p300/CBP for the treatment of castration resistant prostate cancer. 2017 ·Journal of Clinical Oncology ·Neil Pegg, Nigel Brooks, Jenny Worthington, Barbara Young, Amy Prosser, Jordan Lane, (unknown), Richard S. Brown, Gareth W. Harbottle, Jonathan Shannon, Silvia Paoletta, Karen E. Knudsen	23
10	Solid phase synthesis of aryl-ether dendrimers 2001 ·Chemical Communications ·Andrea Basso, Mark Bradley, Brian Evans, Neil Pegg	27
11	Solid-Phase Synthesis of Amidine-Based GP IIb-IIIa Antagonists on Dendrimer Resin Beads 2000 ·European Journal of Organic Chemistry ·Andrea Basso, Neil Pegg, Brian Evans, Mark Bradley	15
12	Synthetic [5,5] trans-fused indane lactones as inhibitors of thrombin 1999 ·Bioorganic & Medicinal Chemistry Letters ·Martin Pass, (unknown), Steven J. Coote, Harry Finch, (unknown), (unknown), Edward McDonald, (unknown), Martin Owen, Neil Pegg, Christopher J. Mooney, (unknown), (unknown), Champa Patel	9
13	5,5-Trans lactone-containing inhibitors of serine proteases: Identification of a novel, acylating thrombin inhibitor 1998 ·Bioorganic & Medicinal Chemistry Letters ·Harry Finch, Neil Pegg, (unknown), (unknown), (unknown), (unknown), (unknown), John G. Montana, Martin Owen, (unknown), (unknown), Barry C. Ross, Callum J. Campbell, C. J. Dix, Christopher J. Mooney, (unknown), Champa Patel	13
14	Reaction of α-amino esters and α-amino ester imines with thiiranium ion intermediates. Application to the synthesis of new potential aminopeptidase inhibitors and mechanistic implications 1997 ·Tetrahedron ·D. Michael Gill, Neil Pegg, Christopher M. Rayner	4
15	Tetrazole NK1 receptor antagonists: The identification of an exceptionally potent orally active antiemetic compound 1996 ·Bioorganic & Medicinal Chemistry Letters ·Duncan Armour, Kyeongwoon Chung, Miles Congreve, Brian Evans, Stephen B. Guntrip, Thomas Hubbard, (unknown), David Middlemiss, J.E. Mordaunt, Neil Pegg, V. Vinader, P. Ward, (unknown)	34
16	The synthesis of a conformationally restrained, combined thromboxane antagonist / synthase inhibitor using an intramolecular ‘Stille’- or ‘Grigg’-palladium-catalysed cyclisation strategy 1993 ·Tetrahedron Letters ·Harry Finch, Neil Pegg, Brian Evans	22
17	Functionalization reactions of a medium-ring bridgehead enone that skirt transannular bond formation 1991 ·The Journal of Organic Chemistry ·Neil Pegg, Leo A. Paquette	11
18	Synthesis of grevillins, novel pyrandione pigments of fungi. Biogenetic interrelationships between grevillins, pulvinic acids, terphenylquinones and xylerythrins 1991 ·Journal of the Chemical Society Perkin Transactions 1 ·Gerald Pattenden, Neil Pegg, Ronald W. Kenyon	22
19	Direct oxygenation of enolates generated by anionic oxy-Cope rearrangement. Expedient preparation of polycyclic .alpha.-hydroxy ketones 1989 ·The Journal of Organic Chemistry ·Leo A. Paquette, (unknown), Neil Pegg, Richard T. Taylor, Thomas M. Zydowsky	28
20	Synthesis of grevillins and their biogenetic interrelationship with terphenylquinones, xylerythrins and pulvinic acid 1987 ·Tetrahedron Letters ·Gerald Pattenden, Neil Pegg, Ronald W. Kenyon	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact